Aggressive cancers often express E-cadherin in cytoplasmic vesicles rather than on the plasma membrane and this may contribute to the invasive phenotype of these tumors. Therapeutic strategies are not currently available that restore the anti-invasive function of E-cadherin in cancers. MDA-MB-231 cells are a frequently used model of invasive triple-negative breast cancer, and these cells express low levels of E-cadherin that is mislocalized to cytoplasmic vesicles. MDA-MB-231 cell lines stably expressing wild-type E-cadherin or E-cadherin fused to glutathione S-transferase or green fluorescent protein were used as experimental systems to probe the mechanisms responsible for cytoplasmic E-cadherin localization in invasive cancers. Although E-cadherin expression partly reduced cell invasion in vitro, E-cadherin was largely localized to the cytoplasm and did not block the invasiveness of the corresponding orthotopic xenograft tumors. Further studies indicated that the glucocorticoid dexamethasone and the highly potent class I histone deacetylase (HDAC) inhibitor largazole cooperated to induce E-cadherin localization to the plasma membrane in triple-negative breast cancers, and to suppress cellular invasion in vitro. Dexamethasone blocked the production of the cleaved form of the CDCP1 (that is, CUB domain-containing protein 1) protein (cCDCP1) previously implicated in the pro-invasive activities of CDCP1 by upregulating the serine protease inhibitor plasminogen activator inhibitor-1. E-cadherin preferentially associated with cCDCP1 compared with the full-length form. In contrast, largazole did not influence CDCP1 cleavage, but increased the association of E-cadherin with g-catenin. This effect on E-cadherin/g-catenin complexes was shared with the nonisoform selective HDAC inhibitors trichostatin A (TSA) and vorinostat (suberoylanilide hydroxamic acid, SAHA), although largazole upregulated endogenous E-cadherin levels more strongly than TSA. These results demonstrate that glucocorticoids and HDAC inhibitors, both of which are currently in clinical use, cooperate to suppress the invasiveness of breast cancer cells through novel, complementary mechanisms that converge on E-cadherin.
INTRODUCTION
Basal-like breast tumors are largely overlapping with the triplenegative subtype defined by low estrogen receptor, progesterone receptor and Her2 expression, and tend to be locally invasive and recur at high frequency. 1, 2 Animal modeling and human studies suggest that E-cadherin functions as a tumor suppressor and an invasion suppressor.
3 E-cadherin is often absent or nonfunctional in invasive breast cancers and this is commonly attributed to epigenetic silencing of the E-cadherin gene, Cdh1. 4 Efforts toward reactivating E-cadherin expression therefore, may have therapeutic implications. 5, 6 However, E-cadherin levels are maintained in some invasive breast cancers although it is mislocalized to cytoplasmic vesicles. 7, 8 These data suggest that reinstating E-cadherin expression may not restore its tumor and invasion suppressive actions unless the posttranslational mechanisms that nullify E-cadherin function in cancers are also blocked. E-cadherin is a homophilic cell-cell adhesion molecule whose extracellular domain binds to surface E-cadherin on adjacent cells while its cytoplasmic tail is a platform for recruitment of p120 ctn , b-catenin and g-catenin. The latter two proteins interact with a-catenin that in turn directly or indirectly couples the E-cadherin complex with the actin cytoskeleton. These multiprotein E-cadherincontaining complexes have a critical physical role in mediating the formation of adherens junctions in epithelial tissues, 9 and control the subcellular trafficking and activity of several transcriptional regulators. 10, 11 It is important therefore, to define the mechanisms responsible for E-cadherin mislocalization in invasive cancers.
E-cadherin was found to complex with the same proteins in both luminal and basal-like breast cancer cells, but the binding stoichiometry to g-catenin versus b-catenin differed. MDA-MB-231 cells stably expressing E-cadherin-green fluorescent protein (E-Cad-GFP) or E-cadherin-glutathione S-transferase (E-Cad-GST) fusion proteins were used as model systems to identify agents that relocalize E-cadherin from cytoplasmic vesicles to the plasma membrane, facilitate cell-cell adhesion and attenuate invasion. The glucocorticoid dexamethasone and the novel histone deacetylase (HDAC) inhibitor largazole 12, 13 each partially restored E-cadherin membrane localization and suppressed invasion, and the combination of these agents was more effective than either compound alone. Dexamethasone blocked the cleavage of the pro-invasive protein CUB domain-containing protein 1 (CDCP1) by upregulating the serine protease inhibitor plasminogen activator inhibitor-1 (PAI-1), preventing the preferential interaction of the cleaved form of CDCP1 with E-cadherin. HDAC inhibitors, in contrast, selectively increased E-cadherin interaction with g-catenin.
Collectively, these results demonstrate that dexamethasone and largazole cooperatively suppress the invasiveness of triple-negative breast cancer cells in vitro, and restore E-cadherin membrane localization and cell-cell junctions in cell culture as well as in ex vivo tumors and intact tumors in vivo.
RESULTS E-cadherin is nonfunctional in invasive breast cancer cells even when it is expressed at high levels MDA-MB-231 and T47D cell lines were engineered to stably express E-cadherin fused with either GFP or GST, and the resulting cell lines were analyzed by immunoblot in comparison with the corresponding vector control cell lines transduced with the empty retroviral vector encoding the Neomycin resistance gene (Figure 1a ). Cadherin 11 has been implicated in increased breast cancer invasiveness and is expressed in the MDA-MB-231 cells, 14 ,15 therefore we examined whether forced E-cadherin expression alters Cadherin 11 levels. E-Cad-GST, but not wildtype E-cadherin or E-Cad-GFP, was consistently observed to significantly decrease Cadherin 11 levels suggesting that increased GST rather than E-cadherin expression suppresses steady-state Cadherin 11 levels. Fluorescence microscopy indicated that E-Cad-GFP localizes to cell-cell junctions in the T47D cells, but is cytoplasmic in MDA-MB-231 cells (Figure 1b , top panel) and it has a similar subcellular distribution to endogenously expressed E-cadherin ( Figure 1b, bottom panel) . MDA-MB-231 cells stably expressing E-Cad-GFP exhibited the same properties as the parental MDA-MB-231 cells when injected into the mammary fat pads of athymic nude mice, including the formation of tumors that lack a defined tumor-stroma boundary and invasion into the adjacent mammary gland (Figure 1c) . Clearly, E-Cad-GFP expression was retained during tumor formation and growth (Figure 1d ), and did not block tumor invasion in vivo. These data suggest that in addition to low E-cadherin expression levels, E-cadherin function is suppressed in MDA-MB-231 cells. Figure 1 . Cellular models for studying E-cadherin regulation in breast cancer cells in vitro and in vivo. (a) Immunoblot analyses of MDA-MB-231 cells engineered to stably express E-cadherin fused C-terminally to GFP (231/E-Cad-GFP), E-cadherin fused C-terminally to GST (231/E-Cad-GST), or stably transduced with the retroviral vector lacking an insert, but conferring neomycin resistance (231/neo). The upper arrow represents the E-cadherin-GST or -GFP fusion proteins and the lower arrow denotes endogenous E-cadherin. (b) Fluorescence microscopy of the indicated cell lines showing intracellular localization of the E-Cad-GFP fusion protein (green, upper panels), and endogenous E-cadherin in the parental cell lines (green, lower panels). DAPI was used as a nuclear counterstain. (c) Hematoxylin and eosin (H&E) stained sections of orthotopic xenograft tumors derived from the indicated cell lines displaying tumor invasion into the mouse mammary fat pad. Yellow arrows in the 231/E-Cad-GFP sample highlight the same region shown at low and high magnifications. E-cadherin forms complexes with adherens junction components in invasive breast cancer cells, but with an altered ratio of b-catenin versus g-catenin binding E-cadherin-GST complexes were isolated from the membrane fractions of the T47D/E-GST and 231/E-GST cell lines by affinity chromatography using glutathione-agarose and analyzed by SDS-PAGE/silver stain ( Figure 2a , left panel) and proteomics using iTRAQ labeling. The proteomics results were verified by immunoblot (Figure 2a, right panel) . E-cadherin-containing complexes were similar between the two cell lines with the exception that the ratio of g-catenin to b-catenin bound with E-cadherin was significantly higher in the T47D cells as compared with the MDA-MB-231 cells. This difference may be partly explained by the relatively high levels of g-catenin expression in the T47D cells as compared with the MDA-MB-231 cells. Similar results were obtained if E-cadherin complexes were isolated by immunoprecipitation using antibodies to E-cadherin or GST (Figure 2b ). These findings suggested that the relatively low level of g-catenin expression in MDA-MB-231 cells might be responsible for the localization of E-cadherin to the cytoplasm. To test this hypothesis, we generated MDA-MB-231 cell lines stably expressing hexahistidine tagged g-catenin (g-catenin-His 6 ), or expressing g-cateninHis 6 in combination with E-cadherin, E-Cad-GFP or E-Cad-GST.
Immunoblot analysis indicated that each of the proteins was expressed as expected ( Figure 2c ). Interestingly, a-catenin was expressed at very low levels in the control 231/neo cells transduced with the empty retroviral vector as compared with the cell lines overexpressing E-Cadherin or g-catenin either separately or together. However, despite the increased expression of a-catenin and g-catenin in the doubly transduced stable cell lines, the resulting cell lines exhibited a mesenchymal morphology similar to that of the parental MDA-MB-231 cells and did not form colonies when grown in culture, indicating a lack of cell-cell adhesion (not shown). These results (Figures 1 and 2) suggest that the diminished E-cadherin function in MDA-MB-231 cells is not simply because of decreased E-cadherin, g-catenin, or a-catenin expression. One hypothesis is that additional post-translational mechanisms are operative that prevent proper E-cadherin membrane localization and function in MDA-MB-231 cells, and that it may be possible to antagonize these mechanisms pharmacologically.
Dexamethasone and largazole cooperate to restore the formation of adherens junctions in invasive breast cancer cells and to block their invasion The 231/E-GFP cell line was treated with a series of small molecule signaling agonists and antagonists to identify compounds that modulate E-cadherin subcellular localization, including Gö 6983, Gö 6976, TGFb, TGFb RI receptor kinase inhibitor, U0126, nocodazole, paclitaxel, PD0332991, CVT313, IC261, SU11274, MG132, apratoxin A, tunicamycin, rapamycin, LiCl, PMA, FK506, cyclosporine A, calyculin A, Y27632, PP1, dasatinib, lapatinib, JAK inhibitor I (EMD Millipore, Billerica, MA, USA), tubacin, chloroquine, GM6001, dexamethasone and largazole. Of these agents, the glucocorticoid dexamethasone and the highly potent HDAC inhibitor largazole 12, 13 each converted E-cadherin expressing MDA-MB-231 cells, but not the corresponding vector control cell line, to a more epithelial-like cobblestone morphology. The most striking difference was that dexamethasone and largazole, in combination with E-cadherin expression, prevented the cells from overlapping each other (Figure 3a ). This effect was reversed by the glucocorticoid receptor antagonist RU486, and was not observed in the absence of exogenous E-cadherin expression. Dexamethasone and largazole also modestly increased E-cadherin localization to the cell-cell periphery, and combination of the two drugs caused a more complete E-cadherin junctional localization than either agent alone (Figure 3b ). Changes in E-cadherin localization partially overlapped with changes in g-catenin localization. In vitro invasion assays were performed to determine the respective effects of E-cadherin expression and Dex. þ Larg. (Dex. þ Larg.) treatment on the invasiveness of MDA-MB-231 cells. E-cadherin expression and dexamethasone and largazole treatment each decreased invasiveness, and combined E-cadherin expression and Dex.þ Larg. treatment reduced invasion more than either manipulation alone (Figure 3c) .
Similar experiments were carried out in the BT549 invasive basal-like human breast cancer cell line that expresses a moderate level (see Figure 4d , below) of endogenous wild-type E-cadherin. 16 Dex. and Larg. cooperated to increase the junctional localization of endogenous E-cadherin in BT549 cells (Figure 3d ). These effects were reversed by RU486. Dexamethasone and largazole each suppressed the invasion of BT549 cells in vitro, and combination of the two agents diminished invasion to a greater extent than either one alone (Figure 3e ). Dex. þ Larg. induction of E-cadherin trafficking to the plasma membrane in both the 231/E-Cad-GFP and BT549 cell lines, as compared with the vehicle control, was quantitated in Figure 3f . Dex. þ Larg. increased junctional E-cadherin 19-fold in the 231/E-Cad-GFP cells and nearly four-fold in the BT549 cells.
Dex. þ Larg. prevents the cleavage of CDCP1, and cleaved CDCP1 associates with E-cadherin Dissolution of adherens junctions can be caused by the activation of tyrosine kinases such as c-Src or c-Met, and this is associated with tyrosine phosphorylation of adherens junction components such as b-catenin and E-cadherin. [17] [18] [19] It was important to determine, therefore, whether dexamethasone treatment causes changes in the patterns of cellular protein tyrosine phosphorylation. Immunoblot analysis of MDA-MB-231 cell lysates with two different antiphosphotyrosine antibodies revealed a band of B80 kDa that vanished upon treatment of the cells with Dex. þ Larg. (Figure 4a ). Proteins from the same extracts were immunoprecipitated with an anti-phosphotyrosine antibody and the immunoprecipitates were resolved by SDS-PAGE and visualized by colloidal Coomassie staining. A doublet in the vicinity of the 80 kDa molecular weight marker was digested with trypsin and subjected to mass spectrometry. Ten of the peptides identified corresponded to the 130 kDa protein isoform 1 of CDCP1 (Figure 4b ). CDCP1, also independently discovered as trask, 20 is a heavily tyrosine phosphorylated protein that has been implicated in cancer invasiveness, [21] [22] [23] suggesting that the effects of Dex. þ Larg. treatment on CDCP1 might be relevant to the anti-invasive properties of these drugs. Interestingly, all of the peptides identified were C-terminal to the known Matriptase cleavage site of CDCP1.
24 CDCP1 cleavage is associated with its increased tyrosine phosphorylation, and the C-terminal, integral membrane fragment may mediate CDCP1 anti-adhesive activity. [24] [25] [26] Matriptase cleavage of CDCP1 produces a C-terminal fragment of B80 kDa, suggesting that Dex. þ Larg. treatment may prevent CDCP1 proteolytic cleavage.
Immunoblot analysis with a CDCP1 antibody displayed the same pattern of bands observed with the anti-phosphotyrosine antibodies in which the full-length form is present, but the cleaved form of CDCP1 (cCDCP1) is absent when the cells were treated with Dex. þ Larg. (Figure 4c ). These results further support the notion that Dex. þ Larg. treatment prevents CDCP1 cleavage. Immunoblot analysis of a panel of 14 human breast cancer cell lines showed that 11 of the lines exhibit a significant level of CDCP1 expression (Figure 4d ). The ratio between the full length and cleaved forms varies among the cell lines that express CDCP1. Immunoblot analysis of extracts from MDA-MB-231 or BT549 cells treated with various combinations of dexamethasone, largazole and RU486 demonstrated that dexamethasone blocks CDCP1 cleavage in the MDA-MB-231 cells and this is partially reversed by RU486 (Figure 4e ). In contrast, in BT549 cells dexamethasone decreased the total levels of CDCP1, and this effect was reversed by RU486. This suggests that dexamethasone may have dual regulatory effects on CDCP1; in some cell lines blocking CDCP1 cleavage and in other lines blocking its expression.
Although CDCP1 interacts with P-cadherin and N-cadherin, 20 it is unknown whether CDCP1 associates with E-cadherin. E-cadherin immunoprecipitation experiments showed that cCDCP1 binds E-cadherin, and that Dex. þ Larg. treatment blocks the formation of this complex by preventing CDCP1 cleavage in MDA-MB-231 cells ( Figure 4f ). Recombinant adenoviruses encoding C-terminally FLAG-tagged full length, wild-type CDCP1 or a CDCP1 deletion mutant corresponding to cCDCP1 (DCDCP1) were used to examine their interaction with E-cadherin. An additional CDCP1 mutant (CDCP1-CSM) was constructed in which the matriptase cleavage site QSRkKFV, where 'k' denotes the cleavage site, was mutated to QSSSFV. FLAG antibody immunoprecipitations indicated that DCDCP1 interacted more avidly with E-cadherin than either CDCP1 or CDCP1-CSM (Figure 4g ). The short form of CDCP1 appeared to be more heavily tyrosine phosphorylated than the full length forms, consistent with previous observations. 25,26 cCDCP1 binds to c-Src 20, 27 and participates in the tyrosine phosphorylation-dependent activation of PKCd. 28 c-Src and PKCd disrupt adherens junctions and induce cytoplasmic localization of E-cadherin. 29 Therefore, it is tempting to speculate that cCDCP1 targets c-Src and PKCd to adherens junctions, resulting in their dissolution, and that dexamethasone prevents loss of cell-cell adhesion by blocking the proteolytic production of cCDCP1.
Dexamethasone controls CDCP1 cleavage through the upregulation of PAI-1 Dexamethasone might control CDCP1 cleavage either by downregulating a relevant protease or by increasing the levels of a protease inhibitor. Dexamethasone upregulated the serine protease inhibitor PAI-1 in the MDA-MB-231 cells, consistent with other findings, 30 and this correlated with reduced CDCP1 cleavage ( Figure 5a ). TGFb also upregulated PAI-1 expression and similarly blocked CDCP1 cleavage. MDA-MB-231 cells secrete plasminogen activators, 30 which convert plasminogen to plasmin, a protease that, in turn, effectively cleaves CDCP1. 25, 26 Therefore, it is expected that CDCP1 cleavage will decrease in cells grown in low serum medium, or medium that promotes the upregulation of PAI-1. Growth of MDA-MB-231 cells in low serum (0.1%) medium supplemented with insulin, transferrin and selenium inhibited CDCP1 cleavage (Figure 5b ), likely because of the combined effect of decreased (serum-derived) plasminogen and insulininduced upregulation of PAI-1 expression. 31, 32 Previous studies have implicated CDCP1 cleavage in increased tyrosine phosphorylation of cCDCP1, coincident with increased signaling functions. 25, 26 Together the results in Figures 5a and b indicate that the components of cell culture media including serum levels, supplementation with glucocorticoids such as dexamethasone and hydrocortisone, supplementation with insulin, as well as factors produced by the cancer cells themselves, such as TGFb, and the plasminogen activators uPA and tPA have important roles in controlling CDCP1 cleavage, and consequently its tyrosine phosphorylation and biological activity.
A recombinant adenovirus encoding PAI-1 was constructed to determine whether PAI-1 expression is sufficient to block CDCP1 cleavage. As indicated in Figures 5c and d , PAI-1 expression largely blocked CDCP1 cleavage in MDA-MB-231, MDA-MB-468 and BT549 cells and completely blocked CDCP1 cleavage in T47D cells.
HDAC inhibitors preferentially increase E-cadherin association with g-catenin
Numerous reports have demonstrated that HDAC inhibitors increase E-cadherin expression in certain cancer cell lines where it is epigenetically silenced. Therefore, we examined whether largazole increases E-cadherin expression. Largazole upregulated E-cadherin in a time-and dose-dependent manner (Figure 6a ) to a significantly greater extent than did Trichostatin A (TSA). Three observations suggested that this increased E-cadherin expression could not completely explain the effects of largazole on cellular behavior: (1) The most striking effects of largazole were on E-cadherin localization rather than its cellular levels. (2) The increased levels of E-cadherin in the MDA-MB-231 cells are below the steady-state endogenous levels of E-cadherin present in more epithelial-like cancer cell lines such as T47D and (3) maximal Dex. þ Larg.-induced changes in cell morphology and cell adhesion require exogenous E-cadherin expression in MDA-MB-231 cells.
As largazole did not influence CDCP1 cleavage, nor appear to function exclusively through upregulating endogenous E-cadherin expression, it was important to assess whether Largazole alters the subunit composition of E-cadherin-containing complexes. These analyses indicated that largazole preferentially increased g-catenin binding to E-cadherin relative to b-catenin binding (Figure 6b ) without changing the levels of g-catenin. In contrast, dexamethasone did not increase g-catenin binding to E-cadherin, but as expected, decreased cCDCP1 binding to E-cadherin. Affinity purification of complexes containing E-cadherin (E-Cad-GST) and g-catenin (g-Cat-His 6 ) by sequential TALON and glutathioneagarose chromatography further demonstrated that Dex. þ Larg. treatment dramatically increased the stability of E-cadherin/ g-catenin complexes (Figure 6c ).
It is possible that largazole alters E-cadherin association with g-catenin through mechanisms that are independent of HDAC inhibition. Largazole requires a sulfhydryl group that inhibits HDAC activity by binding to its active site zinc ion. [33] [34] [35] In contrast, the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and TSA bind the active site zinc ion via their hydroxamate moieties and are structurally very different from largazole. It was reasoned, therefore, that if largazole increased E-cadherin association with g-catenin by inhibiting HDAC activity, then TSA and SAHA should have similar effects. Indeed, largazole, SAHA and TSA each stabilized E-cadherin/g-catenin complexes to similar extents relative to vehicle treatment (Figure 6d ).
Dexamethasone and largazole cooperate to induce junctional E-cadherin localization in tumor samples ex vivo and in intact tumors in vivo It was necessary to evaluate whether dexamethasone and largazole would induce E-cadherin relocalization to sites of cellcell contact in intact tumor samples ex vivo. For these studies 3 mm cubes of tumor tissue were treated in vitro with DMSO vehicle, dexamethasone, largazole or Dex. þ Larg. and analyzed by multiphoton microscopy for E-cadherin-GFP fluorescence (Figure 7a) , or subjected to hematoxylin and eosin staining (H&E) (Figure 7b ). Dexamethasone and largazole treatment induced E-cadherin localization to cell-cell contacts, whereas in the control samples E-cadherin was nearly uniformly distributed with weak junctional E-cadherin-GFP fluorescence signal evident in some areas. H&E staining demonstrated that vehicle control tumor samples exhibited an irregular periphery with cancer cells budding off the surface. In contrast, dexamethasone, largazole and Dex. þ Larg. induced a sharper tumor boundary and a striking increase in the organization of cancer cells at the tumor border. However, in dexamethasone-and largazole-treated samples, surface cancer cells exhibited an elongated spindle morphology, whereas the surface cancer cells in the Dex. þ Larg. treated samples exhibited an epithelial-like cuboidal morphology. The limit of this effect to the edge of the tumor samples may reflect the inability of the drugs to penetrate into the center of the tumor sample by passive diffusion. Thus, the changes in E-cadherin localization apparent in the fluorescence images were accompanied by alterations in cell-cell adhesion, and the cellular architecture and organization at the surface of the tumor sample.
These ex vivo studies were followed-up by in vivo studies in which animals bearing orthotopic tumors derived from 231/ E-Cad-GFP cells were treated with DMSO vehicle, dexamethasone, largazole or Dex. þ Larg. and analyzed by multiphoton microscopy ( Figure 7c ). Dexamethasone treatment induced E-cadherin localization to cell-cell junctions in some areas, but not others. Largazole alone did not significantly relocalize E-cadherin, but altered the morphology of the cancer cells from an elongated spindle-like appearance to a more cuboidal shape. Dex. þ Larg. caused a more uniform localization of E-cadherin to the plasma membrane, producing a honeycomb-like pattern of E-cadherin-GFP fluorescence. Staining of the tumor samples with Hoechst to label nuclei demonstrated more clearly the striking changes in tumor cell morphology induced by Dex. þ Larg. treatment (Figure 7d) .
We performed coimmunoprecipitation analyses on tumor lysates to examine whether treatment of the animals with dexamethasone, largazole or Dex. þ Larg. altered the composition of E-cadherin-containing complexes in the tumors in vivo (Figure 7e ). Neither drug altered b-catenin or p120 ctn binding to E-cadherin, whereas E-cadherin binding to g-catenin was increased in the context of Dex. þ Larg. treatment.
DISCUSSION

E-cadherin as a therapeutic target in invasive cancers
Overexpression of E-cadherin in invasive breast cancer cell lines dramatically reduces their invasiveness in vitro, 36 and this is consistent with our observations (Figure 3c ). It is important to note, however, that these same E-cadherin overexpressing 231/E-Cad-GFP cells form tumors that invade extensively into the surrounding mammary tissue when grown as orthotopic xenografts (Figure 1c) . Further, E-cadherin is expressed in a subset of invasive cancers, 37, 38 and in some cases E-cadherin expression correlates with a worse prognosis than intermediate levels of expression. 39 These observations indicate that the tumor-and invasion-suppressive functions of E-cadherin are lost in many breast cancers independent of decreased expression. It may be possible therefore, to identify drug combinations that restore E-cadherin anticancer actions in this class of tumors.
Decreased E-cadherin expression in human breast cancers is most commonly a result of epigenetic silencing rather than point mutations or chromosomal deletions. Efforts have focused on using HDAC inhibitors to restore E-cadherin expression in breast cancers.
is observed in clinical triple-negative breast cancer samples (Corsino et al. 7 and Zhang et al.
40
). This suggests that E-cadherin expressed in basal-like breast cancer cells might not be functional even if it is expressed at high levels. The results in Figures 1-7 employing MDA-MB-231 cells expressing exogenous E-cadherin, and BT549 cells expressing endogenous E-cadherin, support this contention and indicate that a therapeutic approach for restoring E-cadherin anticancer activity may require components that reverse epigenetic
Restoring e-cadherin function in invasive cancers ME Law et al silencing of the E-cadherin gene, Cdh1, and elements that restore E-cadherin function at the post-translational level.
CDCP1 as a novel target of dexamethasone action
Dexamethasone suppresses invasion through a number of different mechanisms, [41] [42] [43] however, the present study is the first to our knowledge that links glucocorticoids to E-cadherin through effects on CDCP1 cleavage. It is possible that blockade of CDCP1 cleavage suppresses invasion in part through means independent of E-cadherin. CDCP1 also binds to N-and P-cadherin 20 and Dex. þ Larg. blocks invasion in MDA-MB-231 cells, which express very low levels of endogenous E-cadherin (compare Figures 1d  and 3c) . Further, FAK and CDCP1 tyrosine phosphorylation were recently shown to be reciprocally related, 27, 44 and CDCP1 cleavagedependent increases in CDCP1 tyrosine phosphorylation protect cells from anoikis through mechanisms involving enhanced Src and PKCd tyrosine phosphorylation and activation of the pro-survival kinase Akt. 26 This latter study demonstrated that plasmin is an important regulator of CDCP1 cleavage in vivo. Thus, CDCP1 cleavage and the resultant increased cCDCP1 tyrosine phosphorylation likely regulate cell-cell and cell-substratum adhesion through multiple parallel mechanisms involving FAK, Src, PKCd and cadherins. Our observations demonstrating the role of PAI-1 in mediating the effects of glucocorticoid and TGFb signaling on CDCP1 cleavage provide new insights into the mechanisms controlling CDCP1 cleavage and biological activity.
Increased E-cadherin/g-catenin complex formation as a new mechanism of HDAC inhibitor anticancer activity HDAC inhibitors increase E-cadherin expression in breast cancer cells where it has been epigenetically silenced, 6 and the class I selective largazole is more effective in upregulating E-cadherin expression than the less isoform selective HDAC inhibitor TSA (Figure 6a ). HDAC inhibitors, therefore, may suppress cancer invasion both by increasing E-cadherin expression, and by reinforcing E-cadherin association with g-catenin. To our knowledge, this is the first report that HDAC inhibitors facilitate the formation of E-cadherin/g-catenin complexes. An interesting aspect of this observation is that largazole had little effect on E-cadherin association with b-catenin even though g-and b-catenin are 69% identical and may carry out redundant functions regarding the coupling of E-cadherin to a-catenin. p120 catenin has an important role in localizing E-cadherin to cellcell contacts. 45 Largazole or Dex. þ Larg. did not alter E-cadherin binding to p120 catenin or b-catenin in tumor extracts (Figure 7e ). g-catenin is the only protein known to be present in both adherens and desmosomal junctions. The formation of adherens junctions precedes the formation of desmosomal junctions during cell adhesion, and E-cadherin/g-catenin association may facilitate the formation of desmosomal junctions. 46 Therefore, it will be important to determine what influence, if any, HDAC inhibitors have on desmosomal junctions and the distribution of g-catenin between adherens versus desmosomal junctions. Likewise, the ability of cCDCP1 to bind to desmosomal cadherins should be investigated.
The mechanism by which HDAC inhibitors aid the formation of E-cadherin/g-catenin complexes is unclear and could involve increased acetylation of complex components. Along these lines, b-catenin is regulated by acetylation. 47, 48 Alternately, an indirect mechanism involving transcriptional regulation of components of the complex could be operative.
Potential clinical applications of glucocorticoid and HDAC inhibitor combination therapies Dexamethasone is currently administered before surgery to palliate the pain and nausea associated with mastectomies. 49 The HDAC inhibitors Romidepsin (FK228) and Vorinostat (SAHA) are approved for the treatment of cutaneous T-cell lymphoma. These and other HDAC inhibitors are currently undergoing clinical study for efficacy against multiple types of human cancer. If glucocorticoids and HDAC inhibitors cooperate to suppress cancer invasion and tumor recurrence in animal models with acceptable side effects, then future clinical trials in cancer patients may be warranted. Glucocorticoid signaling in triple-negative breast tumors correlates with a poor prognosis, 50 therefore a more suitable approach might be to mimic the effects of dexamethasone on CDCP1 cleavage through the use of inhibitors of the plasminogen activators uPA and tPA.
Triple-negative breast cancers as a category are largely overlapping with the basal-like subtype and are characterized by local invasion and high rates of postsurgical recurrence. 51, 52 These cancers frequently do not exhibit defined borders. Therefore, recurrence is likely a result of incomplete surgical removal. It is possible that a combination therapy focused on restoring E-cadherin expression and biochemical function could be administered in the neoadjuvant setting to limit local invasion into the surrounding normal tissue in order to produce a more defined tumor boundary, resulting in reduced rates of cancer relapse and improved patient survival rates.
MATERIALS AND METHODS
Preparation of cell extracts and immunoblot analysis
Cells were grown in Dulbecco's modified Eagle's medium (SH30003.03; Hyclone Laboratories Inc., Logan, UT, USA) supplemented with 10% fetal bovine serum (10% FBS-DMEM) in a humidified 37 1C incubator with 5% CO 2 . Cell extraction was performed as described previously 53 using buffer containing 1% Triton X100, 20 mM HEPES (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.1% b-mercaptoethanol, 5% glycerol, 10 nM microcystin, 200 mM Na 3 VO 4 and 40 mM Na 2 H 2 P 2 O 7 . Immunoblots were probed with antibodies specific 3 ) excised from mouse tumors derived from 231/E-Cad-GFP cells were treated in vitro with 0.1% DMSO vehicle or 100 nM dexamethasone þ 10 nM largazole and imaged using a multiphoton microscope. Treatments were carried out for 6 days with the treatment solutions being replaced after 4 days. (b) Phase contrast micrographs of the outer edges of treated tumor samples generated as in Figure 7a stained with hematoxylin and eosin. (c) Multiphoton imaging of the E-cadherin-GFP fluorescence of intact 231/E-Cad-GFP tumors from mice treated for six consecutive days with DMSO vehicle control, 10 mg/kg dexamethasone, 10 mg/kg largazole or 10 mg/kg dexamethasone þ 10 mg/kg largazole. (d) Multiphoton imaging of tumors from animals treated as in Figure 7c , except that in addition the tumors were incubated with Hoechst dye to visualize cell nuclei. (e) Extracts from tumors generated as in Figure 7c , d were subjected to immunoprecipitation with an E-cadherin antibody and the immunoprecipitates and the corresponding crude tumor lysates were analyzed by immunoblot.
for Actin (sc-1616R), b-catenin (sc-7199), N-cadherin (sc-7939) , P-cadherin (sc-7893), phosphotyrosine (sc-7020 (PY99)) and g-catenin (sc-7900) purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; antibodies specific for Smad2 (#3102), phospho-Smad2 (#3101), a-catenin (#3236) and CDCP1 (#4115) from Cell Signaling Technology, Danvers, MA, USA; antibodies specific for phosphorylated tyrosine (Cat. 05-321 (4G10)) and Acetyl histone H3 from Millipore, Billerica, MA, USA; antibodies specific for E-cadherin (610182), PAI-1 (612024) and p120
Ctn (610133) from BD Biosciences, Franklin Lake, NJ, USA; and antibodies specific for g-catenin (138500) and cadherin 11 (321700) from Invitrogen, Carlsbad, CA, USA. Cells were treated with dexamethasone (S1322; Selleck Chemicals, Houston, TX, USA), RU486 (10006317; Cayman Chemical, Ann Arbor, MI, USA), Vorinostat (S1047; Selleck Chemicals), TGFb type I receptor kinase inhibitor (616451; EMD Biosciences, San Diego, CA, USA) or TSA (T8552, Sigma-Aldrich, St Louis, MO, USA) at the doses and for the durations indicated in the figure legends. Largazole was synthesized as described previously. 13 Fluorescence and immunofluorescence microscopy Fluorescence and immunofluorescence microscopy were performed essentially as described previously 7 employing antibodies to E-cadherin (610182; BD Bioscience) and g-catenin (138500; Invitrogen).
In vitro invasion assays
Invasion assays were performed using BD BioCoat Matrigel Invasion Chambers (Cat. 354481) according to the manufacturer's instructions. Cells for invasion assays were treated for 72 h with dexamethasone, largazole or Dex. þ Larg. and removed from the flasks with trypsin/EDTA and washed twice in 10% FBS-DMEM to remove traces of the trypsin used to detach the cells from the culture flasks. The cells were counted, diluted and added to the upper chambers of the apparatus in the continued presence of the treatment solutions in medium containing 0.2% FBS. The lower chambers also contained drug treatments, but were supplemented with 10% FBS. Invasion was allowed to proceed for 48 h. Non-invaded cells were removed and cells that had invaded were stained with crystal violet. The assays were performed in triplicate and for each replicate; cells were counted in five random microscope fields. Experiments were repeated three times with similar results.
Orthotopic tumor studies
Cultured tumor cells were removed from the culture flasks with trypsin/ EDTA, washed twice with 10% FBS-DMEM, twice with sterile saline and counted. Cells (2 Â 10 6 ) were injected into the right inguinal (#4) mammary fat pad of 3-5-week-old female athymic nude (nu/nu) mice (Charles Rivers International, Inc., Wilmington, MA, USA) in 100 ml of sterile saline. For analysis of tumor invasion into the mammary fat pad the animals were killed when the tumors reached 2-3 mm in diameter and the mammary glands were excised, fixed with 4% paraformaldehyde, paraffin embedded, sectioned and stained with H&E. Tumor extracts for immunoblot analysis were prepared as described previously. 54 All studies involving animals were approved by the University of Florida Institutional Animal Care and Use Committee.
Multiphoton microscopy
For ex vivo tumor studies, 231/E-Cad-GFP tumors were excised from animals and cut into 3 mm cubes. Each cube was transferred to a well of a six-well plate and treated with 0.1% DMSO vehicle, 100 nM dexamethasone, 10 nM largazole or 100 nM dexamethasone þ 10 nM largazole in 10% FBS-DMEM. Treatments were carried out for 6 days with the treatment solutions being replaced after 4 days. Treated tumor samples were fixed overnight with 4% paraformaldehyde in PBS. The treated, fixed tumor samples were washed in PBS and cut in half. One half of each tumor sample was stored in PBS at 4 1C for imaging by multiphoton microscopy, and the other half was subjected to paraffin embedding, followed by staining with H&E. For in vivo tumor studies, mice bearing 231/E-Cad-GFP tumors were injected daily with 50 ml DMSO vehicle, 10 mg/kg dexamethasone, 10 mg/kg largazole or 10 mg/kg dexamethasone þ 10 mg/kg largazole. Animals were treated once daily for a total of 6 days. Tumors were dissected out 2 h after the final injections and analyzed as described above for the ex vivo tumor samples.
The E-Cad-GFP-labeled tumor tissues were placed over a glass coverslip on the stage of a Zeiss LSM510 equipped with a multiphoton microscope (Zeiss, Thornwood, NY, USA). Images were collected with a Â 40 waterimmersion objective lens. GFP was excited with 780 nm from a Chameleon Ultra Ti-Sapphire pulsed laser (Coherent Inc., Santa Clara, CA, USA) and images were collected through a 500-550-nm band pass filter. Five images were randomly collected for each sample through a thickness of 70 mm.
Design of viral cDNA expression constructs and adenovirus construction
Construction of g-catenin constructs: Human g-catenin was PCR amplified from the Addgene (Cambridge, MA, USA) plasmid 16827 encoding g-catenin in pcDNA3 to add a 5 0 -BamHI site, a 3 0 -His 6 tag and an EcoRI site 3 0 to g-catenin. The primers used to amplify g-catenin were as follows: 5 0 -TTTTGGATCCATGGAGGTGATGAACCTGATG-3 0 and 5 0 -TTTTGAATTCCTAA TGATGATGATGATGATGGGCCAGCATGTGGTCTGC-3 0 . PCR amplified g-catenin-His 6 was subsequently digested with BamHI and EcoRI and cloned into the corresponding restriction sites of pBabe-Puro (Addgene plasmid 1764 55 ). To generate adenovirus expressing g-catenin-His 6 , g-catenin-His 6 was excised from the g-catenin-His 6 /pBabe-Puro vector with BamHI and SalI and cloned into the BglII and SalI sites of pShuttle-CMV. 56 The g-catenin-His 6 /pShuttle-CMV vector was recombined with pAdEasy1 in BJ5183 cells using an electroporator set at 200 Ohms, 25 mF and 2.5 kV. Recombinant g-catenin-His 6 /pAdEasy1 linearized with Pac I was transfected into HEK 293 A cells using lipofectamine (Invitrogen), according to manufacturer's instructions. Adenovirus expressing g-catenin-His 6 was subsequently amplified in HEK 293A cells.
Construction of E-cadherin constructs: QuikChange site-directed mutagenesis (Agilant, Santa Clara, CA, USA) was used to add BglII and SpeI sites 5 0 to the stop codon of the cDNA encoding human E-cadherin in the E-cadherin/pMS plasmid using the following primers: 5 0 -GCTGACATG TACGGAGGCGGCGAGGACGACAGATCTAAGCTTACTAGTTAGGGGACGCTAG GTACCGATATCGGCCGGTCCGGCCTAG-3 0 and 5 0 -CTAGGCCGGACCGGCCGA TATCGGTACCTAGCGTCCCCTAACTAGTAAGCTTAGATCTGTCGTCCTCGCCGC CTCCGTACATGTCAGC-3 0 . Restriction digests confirmed the presence of the BglII and SpeI sites. cDNA encoding GFP from Aequorea coerulescens (AcGFP1) was subsequently PCR amplified to add a 5 0 -BamHI site and a 3 0 -SpeI site to GFP. Oligonucleotides used to amplify GFP are as follows: 5 0 -TTTTGGATCCGTGAGCAAGGGCGCCCGAG-3 0 and 5 0 -TTTTACTAGTCTTG TACAGCTCATCCATGCC-3 0 . cDNA encoding GST from Schistosoma japonicum was also PCR amplified to add a 5 0 -BamHI site and a 3 0 -SpeI site. Oligonucleotides used to amplify GST were as follows: 5 0 -TTTTGGATC CATGGCCCCTATACTAGGTTAT-3 0 and 5 0 -TTTTACTAGTACGCGGAACCAGAT CCGATTTTGG-3 0 . PCR amplified GFP and GST were digested with BamHI and SpeI and ligated into the BglII and SpeI sites of E-cadherin/pMS. Thus, GFP and GST were cloned 3 0 to the coding sequence of E-cadherin in E-cadherin/pMS. E-cadherin-GFP and E-cadherin-GST coding regions were subsequently excised from the pMS vector using SfiI and SgfI and cloned into the corresponding sites in LZRS. The LZRS and E-cadherin/pMS plasmids 57, 58 were generously provided by Dr Al Reynolds (Vanderbilt University, Nashville, TN, USA).
Construction of a PAI-1 adenoviral vector
A full length PAI-1 cDNA insert was excised from pcDNA3.1 using 5 0 -KpnI and 3 0 -NotI and cloned into the 5 0 -KpnI and 3 0 -NotI sites of pAdTrack-CMV. PAI-1 cloned into the pAdTrack-CMV vector was used to produce recombinant adenovirus as described above for g-cateninin-His 6 .
Construction of CDCP1 adenoviral vectors cDNA encoding human CDCP1 (accession no. NM_002842) cloned into the SgfI and MluI sites of pCMV6 were purchased from Origene (Rockville, MD, USA) (cat. # RC220633). This plasmid is constructed to encode Myc and DDK tags C-terminal to CDCP1. A SalI restriction site was introduced 3 0 to the stop codon encoded in the CDCP1/pCMV6 vector for the future cloning of CDCP1 into the pAdTrack-CMV vector. QuikChange mutagenesis was used to introduce the SalI restriction site and simultaneously destroy the PmeI and FseI sites in the CDCP1/pCMV6 vector. Oligonucleotides used for mutagenesis are as follows: 5 0 -GACGACGATAAGGTTTAAGTCGACGGCCGC GGTCATAGCTGTTTC-3 0 and 5 0 -GAAACAGCTATGACCGCGGCCGTCGACTT AAACCTTATCGTCGTC-3 0 . QuikChange mutagenesis was subsequently performed using the CDCP1/pCMV6 vector encoding the 3 0 SalI site to delete the region encoding the N-terminus of CDCP1 to produce the short form of CDCP1 (referred to as DCDCP1). Oligonucleotides used for mutagenesis are as follows: 5 0 -CTGCCACGAGAAAGCAACTTTGTCCCT GGCTGTTTCGTG-3 0 and 5 0 -CACGAAACAGCCAGGGACAAAGTTGCTTTCTCGT Restoring e-cadherin function in invasive cancers ME Law et al GGCAG-3 0 . Furthermore, the cDNA encoding the matriptase cleavage site in CDCP1 was mutated using the following oligonucleotides: 5 0 -CGGCCC GTCAAACAGAGCTCCTCGTTTGTCCCTGGCTGTTTC-3 0 and 5 0 -GAAACAGCCA GGGACAAACGAGGAGCTCTGTTTGACGGGCCG-3 0 . This mutation changed the Arg and Lys residues in the Matriptase cleavage site to two Ser residues (referred to as CDCP1-CSM).
To generate adenovirus expressing CDCP1, DCDCP1 or CDCP1-CSM, cDNA encoding these constructs was digested from pCMV6 using the 5 0 -KpnI and 3 0 -SalI restriction sites. cDNA encoding CDCP1, DCDCP1 and CDCP1-CSM was cloned into the 5 0 -KpnI and 3 0 -XhoI sites of pAdTrack-CMV. The CDCP1, DCDCP1 and CDCP1-CSM constructs in the pAdTrack-CMV vector were used to produce recombinant adenoviruses as described above. All of the constructs described above were verified by DNA sequencing.
Construction of stable cell lines
Viruses produced using the vectors encoding E-cadherin and g-cateninHis 6 described above were packaged using Phoenix cells 59 and the viruses were used to infect the target cell lines as described previously. 53 Cells infected with the E-cadherin vectors were selected with 2 mg/ml G418, and cells infected with the g-catenin-His 6 retroviral vector were selected with 5 mg/ml Puromycin. To produce stable cell lines doubly transduced with E-cadherin and g-catenin, the lines expressing the E-cadherin constructs were infected with the g-catenin-His 6 retroviral vector and the resulting cells were selected with 2 mg/ml G418 þ 5 mg/ml Puromycin.
Affinity purification of E-cadherin complexes and immunoprecipitation
Cells were subjected to hypotonic lysis and membrane fractions were isolated by centrifugation for 1 h at 100 000 Â g. The pellet was solubilized by sonication in buffer containing 2% Triton X100, 20 mM HEPES (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.1% b-mercaptoethanol, 5% glycerol, 10 nM microcystin, 200 mM Na 3 VO 4 and 40 mM Na 2 H 2 P 2 O 7 . The membrane extract was centrifuged for 1 h at 100 000 Â g, and the supernatant was used for E-cadherin purifications. Complexes containing E-Cad-GST were isolated using glutathione-agarose (G4510; Sigma-Aldrich), washed, and either eluted with 5 mM glutathione or eluted by boiling in SDS-PAGE sample buffer. In sequential purifications involving g-catenin-His 6 and E-Cad-GST proteins expressed in the same cells, TALON (635503; Clontech Laboratories, Inc., Mountain View, CA, USA) resin purifications were performed as described previously, 60 and the 400 mM imidazole eluents were diluted 10-fold and purified using glutathione-agarose, followed by elution with 5 mM glutathione. Sequential affinity purification experiments were performed using cells stably expressing both E-Cad-GST and g-cateninHis 6 , or were carried out in 231/E-Cad-GST cells that had been infected with an adenovirus encoding g-catenin-His 6 or an adenovirus encoding GFP as a control. The affinity purifications performed using either strategy produced identical results in terms of the observed effects of dexamethasone and largazole on E-cadherin complexes. Immunoprecipitations were performed as described previously 53 using 2 mg of total protein extract per sample and 4 mg of antibody per sample. Immunoprecipitates prepared using antibodies to E-cadherin (610182; BD Biosciences) or GST (sc-459; Santa Cruz Biotechnology Inc.) were isolated with 35 ml per sample protein G-sepharose (10-1242; Invitrogen), washed, and eluted by boiling in SDS-PAGE sample buffer. Extracts from 231/ECad-GFP tumors were precleared with protein G-sepharose beads before immunoprecipitation analysis of tumor lysates as described previously. 54 Identification of CDCP1 by mass spectrometry Tyrosine phosphorylated proteins were isolated by immunoprecipitation as described above using the 4G10 antiphosphotyrosine antibody (05-321; Millipore) and the proteins were visualized by staining with colloidal Coomassie (LC6025; Invitrogen). A protein doublet of B80 kDa that was present in samples derived from vehicle (DMSO) treated cells, but not in cells treated with 100 nM dexamethasone for 72 h, was excised and digested with trypsin as previously described. 61 The tryptic peptides were separated on an LC Packing (San Francisco, CA, USA) C18 Pep Map HPLC column and LC-MS/MS analysis was carried out on a hybrid quadrupole-TOF mass spectrometer (QSTAR Elite, AB Sciex Inc., Framingham, MA, USA).
Tandem mass spectra were extracted by ABI Analyst version 1.1. All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 2.0.01). Peptide identifications were accepted if they could be established at 495.0% probability as specified by the peptide prophet algorithm. 62 Protein identifications were accepted if they could be established at greater than 99.0% probability and contain at least two identified unique peptides. Protein probabilities were assigned by the protein prophet algorithm. 63 Proteomic comparison of E-cadherin complexes between invasive and noninvasive cancer cell lines by iTRAQ analysis
The two samples being compared represented equal amounts of E-cadherin complexes isolated from either T47D or MDA-MB-231 cells stably expressing the E-Cad-GST fusion protein, by glutathione-agarose affinity chromatography. The samples were reduced, alkylated, trypsindigested and labeled using the iTRAQ Reagents Multiplex kit according to manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The labeled peptides were separated on a MacroSpin Vydac C18 reverse phase minicolumn (The Nestgroup Inc., Southborough, MA, USA). The eluates were dried down and dissolved in strong cation exchange solvent A (25% v/v acetonitrile, 10 mM ammonium formate, pH 2.8). The peptides were fractionated on an Agilent HPLC system 1100 using a polysulfoethyl A column (2.1 Â 100 mm, 5 mm, 300 Å, PolyLC, Columbia, MD, USA).
Each strong cation exchange fraction was lyophilized and redissolved in solvent A (3% acetonitrile v/v, 0.1% acetic acid v/v) plus 0.01% trifluoroacetic acid. The peptides were loaded onto a C18 capillary trap cartridge (LC Packings) and then separated on a 15-cm nanoflow C18 column (PepMap 75 mm id, 3 mm, 100 Å) (LC Packings). The HPLC instrument and the quadrupole time-of-flight (QSTAR Elite) MS system were the same as previously described. 64 The instrument was operated in an information-dependent data acquisition mode where a MS scan followed by three MS/MS scans of four highest abundance peptide ions were acquired in each cycle.
The MS/MS Data were processed by a thorough search considering biological modifications against an IPI human database using the paragon algorithm (Shilov et al., 2007) of ProteinPilot v4.0 software suite (Applied Biosystems).
For relative protein quantification using iTRAQ, only MS/MS spectra unique to a particular protein and where the sum of the signal-to-noise ratio for all of the peak pairs 49 were used for quantification (software default settings, Applied Biosystems). The mean, s.d., and P-values to estimate statistical significance of the protein changes were calculated by ProGroup.
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